scholarly journals Resource Use and Health Care Costs of COPD Patients at the End of Life: A Systematic Review

2016 ◽  
Vol 52 (4) ◽  
pp. 588-599 ◽  
Author(s):  
Kristof Faes ◽  
Veerle De Frène ◽  
Joachim Cohen ◽  
Lieven Annemans
2015 ◽  
Vol 18 (7) ◽  
pp. A507
Author(s):  
K Faes ◽  
V De Frène ◽  
J Cohen ◽  
L Annemans

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6631-6631
Author(s):  
Shelby D. Reed ◽  
Michaela A Dinan ◽  
Yanhong Li ◽  
Yinghong Zhang ◽  
Lesley H Curtis ◽  
...  

6631 Background: Prostate cancer is one of the leading sources of overall cancer care costs among men in the United States. Medical resource use and costs associated with prostate cancer care at the end of life, remain poorly understood. Methods: Retrospective analysis of Surveillance, Epidemiology, and End Results (SEER) -Medicare data was used to characterize changes in resource utilization and health care costs to the Centers for Medicare and Medicaid (CMS) in patients diagnosed with prostate cancer who died of prostate cancer vs. non-prostate causes between 2000 and 2007. Results: A total of 34,727 patients with prostate cancer met study criteria. Patients who died of prostate cancer were significantly more likely to have been diagnosed with incident distant metastatic disease (27% vs. 4%) and had fewer comorbid conditions than patients who died of other causes. In the year prior to death, men who died of prostate cancer had lower mean inpatient costs ($20,769 vs. $29,851), resulting from fewer hospitalizations (1.8 vs. 2.1) and fewer days spent in the hospital (12.2 vs. 15.7) and the ICU (1.4 vs. 3.4) as compared to men who were diagnosed with prostate cancer but died of some other cause (all P< 0.001). Men who died of prostate cancer also had lower rates of SNF utilization (32.8% vs 36.2%) and spent fewer days in SNF institutions (11.7 vs 14.7) (both P< 0.001). Conversely, men who died of prostate cancer were more likely to have enrolled in hospice (62% vs. 28%) with higher mean hospice costs ($5,117 vs. $1,981) (both P< 0.001). The substitution of more hospice care relative to inpatient care for men who died of prostate cancer resulted in lower total health care costs ($42,572 vs. $45,830; P< 0.001) relative to men who died from non-prostate cancer causes. Conclusions: Among men with a diagnosis of prostate cancer who died between 2000 and 2007, those with prostate cancer-specific mortality had lower overall health care costs than those who died from other causes. Less aggressive inpatient care near the end of life may explain the differences in cost. Ongoing investigation of care at the end of life is warranted given recent changes in the treatment landscape of metastatic prostate cancer.


Sensors ◽  
2020 ◽  
Vol 20 (17) ◽  
pp. 5006
Author(s):  
Pau Redón ◽  
Atif Shahzad ◽  
Talha Iqbal ◽  
William Wijns

Diagnosing and treating acute coronary syndromes consumes a significant fraction of the healthcare budget worldwide. The pressure on resources is expected to increase with the continuing rise of cardiovascular disease, other chronic diseases and extended life expectancy, while expenditure is constrained. The objective of this review is to assess if home-based solutions for measuring chemical cardiac biomarkers can mitigate or reduce the continued rise in the costs of ACS treatment. A systematic review was performed considering published literature in several relevant public databases (i.e., PUBMED, Cochrane, Embase and Scopus) focusing on current biomarker practices in high-risk patients, their cost-effectiveness and the clinical evidence and feasibility of implementation. Out of 26,000 references screened, 86 met the inclusion criteria after independent full-text review. Current clinical evidence highlights that home-based solutions implemented in primary and secondary prevention reduce health care costs by earlier diagnosis, improved patient outcomes and quality of life, as well as by avoidance of unnecessary use of resources. Economical evidence suggests their potential to reduce health care costs if the incremental cost-effectiveness ratio or the willingness-to-pay does not surpass £20,000/QALY or €50,000 limit per 20,000 patients, respectively. The cost-effectiveness of these solutions increases when applied to high-risk patients.


2019 ◽  
Vol 47 (8) ◽  
pp. 963-967 ◽  
Author(s):  
Casey Dempsey ◽  
Erik Skoglund ◽  
Kenneth L. Muldrew ◽  
Kevin W. Garey

2020 ◽  
Vol 3 (3) ◽  
pp. e200861
Author(s):  
William B. Weeks ◽  
Stacey Y. Cao ◽  
Chris M. Lester ◽  
James N. Weinstein

2012 ◽  
Vol 8 (6S) ◽  
pp. 75s-80s ◽  
Author(s):  
Benjamin Chastek ◽  
Carolyn Harley ◽  
Joel Kallich ◽  
Lee Newcomer ◽  
Carly J. Paoli ◽  
...  

Oncology costs increase in the last 6 months before death largely because of increased inpatient costs, whereas outpatient costs decrease.


2019 ◽  
Vol 37 (22) ◽  
pp. 1935-1945 ◽  
Author(s):  
Gabrielle B. Rocque ◽  
Courtney P. Williams ◽  
Harold D. Miller ◽  
Andres Azuero ◽  
Stephanie B. Wheeler ◽  
...  

PURPOSEMany community cancer clinics closed between 2008 and 2016, with additional closings potentially expected. Limited data exist on the impact of travel time on health care costs and resource use.METHODSThis retrospective cohort study (2012 to 2015) evaluated travel time to cancer care site for Medicare beneficiaries age 65 years or older in the southeastern United States. The primary outcome was Medicare spending by phase of care (ie, initial, survivorship, end of life). Secondary outcomes included patient cost responsibility and resource use measured by hospitalization rates, intensive care unit admissions, and chemotherapy-related hospitalization rates. Hierarchical linear models with patients clustered within cancer care site (CCS) were used to determine the effects of travel time on average monthly phase-specific Medicare spending and patient cost responsibility.RESULTSMedian travel time was 32 (interquartile range, 18-59) minutes for the 23,382 included Medicare beneficiaries, with 24% of patients traveling longer than 1 hour to their CCS. During the initial phase of care, Medicare spending was 14% higher and patient cost responsibility was 10% higher for patients traveling longer than 1 hour than those traveling 30 minutes or less. Hospitalization rates were 4% to 13% higher for patients traveling longer than 1 hour versus 30 minutes or less in the initial (61 v 54), survivorship (27 v 26), and end-of-life (310 v 286) phases of care (all P < .05). Most patients traveling longer than 1 hour were hospitalized at a local hospital rather than at their CCS, whereas the converse was true for patients traveling 30 minutes or less.CONCLUSIONAs health care locations close, patients living farther from treatment sites may experience more limited access to care, and health care spending could increase for patients and Medicare.


2014 ◽  
Vol 17 (7) ◽  
pp. A625-A626
Author(s):  
M. Ondrusova ◽  
M. Psenkova ◽  
M. Mlyncek ◽  
L. Masak ◽  
L. Hlavinkova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document